Analysts Set Globus Medical, Inc. (NYSE:GMED) Target Price at $101.77

Globus Medical, Inc. (NYSE:GMED) has been assigned a consensus recommendation of “Moderate Buy” from the seventeen analysts that are presently covering the stock, MarketBeat reports. Five analysts have rated the stock with a hold recommendation, nine have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $101.7692.

GMED has been the subject of a number of research reports. BMO Capital Markets began coverage on Globus Medical in a report on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 price objective for the company. Truist Financial decreased their price objective on Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Thursday, July 16th. Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 10th. Piper Sandler cut their target price on Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research note on Monday, June 15th. Finally, UBS Group assumed coverage on shares of Globus Medical in a research report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price target on the stock.

Insider Buying and Selling at Globus Medical

In related news, Director Stephen Zarrilli sold 25,000 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the transaction, the director owned 25,000 shares of the company’s stock, valued at approximately $2,176,000. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 18.38% of the company’s stock.

Institutional Trading of Globus Medical

Institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System increased its holdings in shares of Globus Medical by 7,827.7% in the second quarter. California State Teachers Retirement System now owns 10,326,607 shares of the medical device company’s stock worth $815,905,000 after buying an additional 10,196,347 shares during the period. Janus Henderson Group PLC grew its position in Globus Medical by 4.5% during the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after acquiring an additional 328,217 shares during the last quarter. Invesco Ltd. increased its stake in Globus Medical by 1,235.2% in the 4th quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock worth $339,322,000 after purchasing an additional 3,595,339 shares during the period. Bank of Montreal Can increased its stake in Globus Medical by 15,317.1% in the 4th quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock worth $294,519,000 after purchasing an additional 3,351,380 shares during the period. Finally, Sculptor Capital LP lifted its position in Globus Medical by 1.9% in the first quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock valued at $263,477,000 after purchasing an additional 58,000 shares during the last quarter. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Globus Medical Stock Performance

Globus Medical stock opened at $78.27 on Friday. The firm’s fifty day moving average price is $80.87 and its 200-day moving average price is $84.30. The stock has a market cap of $10.51 billion, a P/E ratio of 20.02, a price-to-earnings-growth ratio of 1.26 and a beta of 0.95. Globus Medical has a fifty-two week low of $54.15 and a fifty-two week high of $101.40.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.24. The company had revenue of $789.61 million during the quarter, compared to the consensus estimate of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The firm’s revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, analysts predict that Globus Medical will post 4.99 earnings per share for the current year.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.